Periocular corticosteroids in diabetic papillopathy

Eye

Volumn 19, Issue 1, 2005, Pages 45-51

  Mansour, A M ^a,b   El Dairi, M A ^a   Shehab, M A ^c   Shahin, H K ^a   Shaaban, J A ^b   Antonios, S R ^d  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Bikhazi Medical Group   (Lebanon)

^c MAKASSED GENERAL HOSPITAL   (Lebanon)

^d RIZK HOSPITAL   (Lebanon)

Author keywords

Diabetic papillopathy; Optic neuropathy; Periocular corticosteroids

Indexed keywords

CORTICOSTEROID;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATARACT; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; ONSET AGE; OPHTHALMOSCOPY; OPTIC DISK ANOMALY; OPTIC NERVE; PROSPECTIVE STUDY; PTOSIS; VISUAL ACUITY; VISUAL FIELD;

EID: 13244271335     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701418     Document Type: Article

References (32)

1. Whittaker KW, Mehta JS, Tsaloumas MD. Bilateral diabetic papillopathy associated with optic disc neovascularisation. Eye 2000; 14: 914-915.
2. Lubow M, Makley TA. Pseudopapilledema of juvenile diabetes mellitus. Arch Ophthalmol 1971; 85: 417-422.
3. Barr CC, Glaser JS, Blankenship G. Acute disc swelling in juvenile diabetes. Clinical profile and natural history of 12 cases. Arch Ophthalmol 1980; 98: 2185-2192.
4. Appen R, Chandra S, Klein R, Myers F. Diabetic papillopathy. Am J Ophthalmol 1980; 90: 203-209.
5. Pavan PR, Aiello LM, Wafai MZ, Briones JC, Sebestyen JG, Bradbury MJ. Optic disc oedema in juvenile-onset diabetes. Arch Ophthalmol 1980; 98: 2193-2195.
6. Regillo CD, Brown GC, Savino PJ, Byrnes GA, Benson WE, Tasman WS et al. Diabetic papillopathy. Patient characteristics and fundus findings. Arch Ophthalmol 1995; 113: 889-895.
7. Bayraktar Z, Alacali N, Bayraktar S. Diabetic papillopathy in type II diabetic patients. Retina 2002; 22: 752-758.
8. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995; 120: 55-64.
9. Sanislo SR, Lowder CY, Kaiser PK, Gutman FA, Zegarra H, Dodds EM et al. Corticosteroid therapy for optic disc neovascularization secondary to chronic uveitis. Am J Ophthalmol 2000; 130: 724-731.
10. Ehrenberg M, McCuen II BW, Schindler RH, Machemer R. Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology 1984; 91: 321-325.
11. Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR. A comparison of retrobulbar versus sub-tenon's corticosteroid therapy for cystoid macular oedema refractory to topical medications. Ophthalmology 1997; 104: 2003-2008.
12. Schimek RA, Newsom SR. Restoration of vision in temporal arteritis by retrobulbar injections of steroids. Am J Ophthalmol 1966; 62: 693-696.
13. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133: 373-385.
14. Arnold AC, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 117: 222-230.
15. Inoue M, Tsukahara Y. Vascular optic neuropathy in diabetes mellitus. Jpn J Ophthalmol 1997; 41: 328-331.
16. Ho A, Maguire A, Yanuzzi L, Fisher Y, Galetta S, Sergott R. Rapidly progressive optic disc neovascularization after diabetic papillopathy. Am J Ophthalmol 1995; 120: 673-675.
17. Friedrich Y, Feiner M, Gawi H, Friedman Z. Diabetic papillopathy with macular star mimicking clinically significant macular oedema. Retina 2001; 21: 80-82.
18. Lee JH, Kim SJ, Chung H. The effect of subtenon injection of methylprednisolone acetate on the breakdown of blood retinal barrier after cryotherapy. Korean J Ophthalmol 1995; 9: 1-6.
19. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003; 44: 1192-1201.
20. Yanagi Y, Tamaki Y, Obata R, Muranaka K, Homma N, Matsuoka B et al. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 2002; 43: 3495-3499.
21. Weijtens O, Schoemaker RC, Lentjes EGWM, Romijn FPHTM, Cohen AF, van Meurs JC. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology 2000; 107: 1932-1938.
22. Weijtens O, Feron EJ, Schoemaker RC, Cohen AF, Lentjes EG, Romijn FP et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol 1999; 128: 192-197.
23. Hyndiuk RA, Reagan MG. Radioactive depot-corticosteroid penetration into monkey ocular tissue. Arch Ophthalmol 1968; 80 499-503.
24. Kunou N, Ogura Y, Honda Y, Hyon SH, Ikada Y. Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate. J Biomed Mater Res 2000; 51: 635-641.
25. Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol 1987; 103: 281-288.
26. Levin DS, Han DP, Dev S, Wirostko WJ, Mieler WF, Connor TB et al. Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. Am J Ophthalmol 2002; 133: 196-202.
27. Lafranco Dafflon M, Tran VT, Guex-Crosier Y, Herbort CP. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol 1999; 237: 289-295.
28. Gopal L, Bhende M, Sharma T. Vitrectomy for accidental intraocular steroid injection. Retina 1995; 15: 295-299.
29. Ozerdem U, Levi L, Cheng L, Song MK, Scher C, Freeman WR. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol 2000; 130: 240-241.
30. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22 143-152.
31. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S et al. Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003; 23: 14-23.
32. Bojic L, Ivanisevic M, Gosovic G. Hyperbaric oxygen therapy in two patients with non-arteritic arterior optic neuropathy who did not respond to prednisone. Undersea Hyperb Med 2002; 29: 86-92.